Ipamorelin + Tesamorelin 10mg
Dual-action GH secretagogue blend combining a selective ghrelin agonist with a stabilized GHRH analog for investigational metabolic research.
Mechanism
This formulation simultaneously activates pituitary GHRH receptors via Tesamorelin and GHS-R1a ghrelin receptors via Ipamorelin to induce coordinated, pulsatile endogenous growth hormone secretion.
Dosing
Initial research protocols begin with 330 mcg of total blend administered subcutaneously once daily (or on a 5-day on, 2-day off schedule).
Reconstitution
Reconstituting the 10 mg blend vial with 3.0 mL of bacteriostatic water results in a final total concentration of approximately 3.33 mg/mL (~1.67 mg/mL per component).
Storage
Preserve the lyophilized blend in deep freeze at -20 °C protected from light, and keep the reconstituted solution refrigerated between 2 °C and 8 °C for up to 28 days without freezing.
Mix & measure Ipamorelin + Tesamorelin 10mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Ipamorelin + Tesamorelin 10mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 30.3
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 | 330 mcg total (1× daily) | 10 units (0.10 mL) |
| Weeks 5–8 | 500 mcg total (1× daily) | 15 units (0.15 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL (or 2.0 mL for higher concentration) of bacteriostatic water into a sterile syringe.
- 2
Release it slowly down the vial's inner wall to limit foaming.
- 3
Swirl or roll the vial gently until both peptides fully dissolve — don't shake.
- 4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Supplies Needed
Peptide Vial
Lyophilized Ipamorelin + Tesamorelin (10 mg total blend, 5 mg each) container requiring careful cold storage and reconstitution.
Insulin Syringes (U-100)
Calibrated 1 mL syringes utilized to precisely draw and administer low-volume microgram research aliquots.
Bacteriostatic Water
Sterile diluent preserved with 0.9% benzyl alcohol used to dissolve lyophilized peptides for multi-use research.
Alcohol Swabs
Sterile pads used to disinfect the rubber vial stopper prior to needle penetration and prepare the injection zone.
Why researchers study it
GH & IGF-1 support
Visceral fat / lipolysis
Body composition
Sleep & recovery
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Ipamorelin + Tesamorelin is a fixed-ratio research peptide formulation combining two distinct secretagogues designed to target pituitary growth hormone pathways simultaneously. The combination incorporates equal parts of Ipamorelin, a selective pentapeptide targeting the growth hormone secretagogue receptor (GHS-R1a), and Tesamorelin, a 44-amino-acid synthetic growth hormone-releasing hormone (GHRH) analog. In preclinical and laboratory settings, this dual-agent approach is investigated to explore whether cross-talk between the GHRH receptor and ghrelin receptor produces enhanced pulsatile GH release compared to monotherapies. Scientific inquiries center on assessing the downstream modulation of circulating IGF-1 concentrations, lipid turnover, and deep abdominal adipose tissue metabolism. Because the peptides are co-lyophilized in an identical 1:1 proportion, experimental models must account for parallel exposure to both active agents upon reconstitution. This compound serves strictly for scientific exploration of the somatotropic axis and is not cleared for therapeutic or human use.
References
- 1.FDA Label, Egrifta (tesamorelin), 2010 — Prescribing information for tesamorelin in HIV-associated lipodystrophy
- 2.Falutz et al., New England Journal of Medicine, 2007 — Effects of tesamorelin on visceral abdominal fat and IGF-1
- 3.Falutz et al., Clinical Infectious Diseases, 2010 — Long-term tesamorelin metabolic safety and visceral fat assessment
- 4.Raun et al., European Journal of Endocrinology, 1998 — Selective growth hormone-releasing properties of the ghrelin agonist ipamorelin
- 5.CDC, Injection Safety Guidelines, 2011 — Clinical injection safety, needle handling, and disposal protocols
- 6.World Health Organization, WHO Best Practices for Injections, 2010 — Standardized procedures for subcutaneous injections and asepsis
- 7.World Anti-Doping Agency, WADA Prohibited List, 2024 — Classification of growth hormone secretagogues under S2 prohibitions
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allFollistatin-344 1mg
Recombinant glycoprotein studied for myostatin inhibition, ActRIIB pathway modulation, and muscle hypertrophy in preclinical models.
View ProtocolPielotax 20 mg oral
Pielotax (A-9) is an oral animal-derived peptide complex explored in preclinical models for renal cellular health and functional protection.
View ProtocolHCG 5000 IU
Human chorionic gonadotropin acts as an LH mimetic to support testicular Leydig cell function, spermatogenesis, and hormonal regulation.
View Protocol